For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
Richard M. Bayney
Advertisement
Articles by Richard M. Bayney
Advertisement
Latest Updated Articles
Portfolio Management Health CheckPublished: May 12th 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
